In this role, Dr. Tarka will lead the clinical development of surlorian (ARM210) as it advances into Phase 2 trials for heart failure with reduced ejection fraction (HFrEF) and ryanodine receptor ...

RyCarma Therapeutics, Inc., a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases, has appointed Elizabeth Tarka, M.D., ...